Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small-Cell Lung Cancer [0.03%]
可切除肺EGFR突变非小细胞癌的表新辅助奥希替尼治疗
Jianxing He,Masahiro Tsuboi,Walter Weder et al.
Jianxing He et al.
Purpose: Adjuvant osimertinib is standard-of-care for patients with resected epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). Neoadjuvant treatment could improve surgical and long-term o...
Suresh S Ramalingam,Thomas E Stinchcombe
Suresh S Ramalingam
Long-term Efficacy and Safety of Lifileucel Tumor-infiltrating Lymphocyte (TIL) Cell Therapy in Patients with Advanced Melanoma: A 5-year Analysis of the C-144-01 Study [0.03%]
抗黑色素瘤肿瘤浸润淋巴细胞(Lifileucel)治疗5年疗效及安全性：C-144-01研究的长期随访结果
Theresa Medina,Jason A Chesney,Harriet M Kluger et al.
Theresa Medina et al.
Patients with advanced melanoma resistant to immune checkpoint or BRAF/MEK inhibitors have treatment options with relatively low efficacy. Lifileucel, a one-time autologous tumor-infiltrating lymphocyte cell therapy, was approved in the US ...
Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase 1 Study [0.03%]
一种新型双特异性T细胞衔接器药物Pasrotamig(针对人肥大反应性丝氨酸蛋白酶2)，在转移性去势抵抗型前列腺癌中疗效的I期研究
Mark N Stein,Armelle Vinceneux,Debbie Robbrecht et al.
Mark N Stein et al.
Background: We report Phase 1 trial results for pasritamig, a first-in-class, T-cell engaging bispecific antibody targeting human kallikrein 2 (KLK2) expressed on the surface of prostate cancer (PC) cells. ...
Zipalertinib in Patients With EGFR Exon 20 Insertion-Positive NSCLC Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab [0.03%]
用于治疗铂类化疗（单药或与安维汀珠单抗联用）后疾病进展的带有EGFR外显子20插入突变的非小细胞肺癌患者的zacrossibitinib治疗
Zofia Piotrowska,Antonio Passaro,Danny Nguyen et al.
Zofia Piotrowska et al.
Purpose: To evaluate the safety and efficacy of zipalertinib, an irreversible epidermal growth factor receptor (EGFR) inhibitor, in pretreated patients with non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insert...
Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study [0.03%]
仑伐替尼联合帕博利珠单抗和化疗与化疗一线治疗晚期胃食管腺癌：LEAP-015 Ⅲ期随机试验
Kohei Shitara,Sylvie Lorenzen,Jin Li et al.
Kohei Shitara et al.
Purpose: The phase III randomized open-label LEAP-015 study (ClinicalTrials.gov identifier: NCT04662710) evaluated first-line lenvatinib plus pembrolizumab and chemotherapy versus chemotherapy for advanced metastatic gast...
Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/ TP53 Mutation: SEQUOIA Arm D Results [0.03%]
zanubrutinib联合venetoclax治疗伴或不伴有del（17p）/TP53突变的初治慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者：SEQUOIA注册临床研究Arm D结果
Mazyar Shadman,Talha Munir,Shuo Ma et al.
Mazyar Shadman et al.
Purpose: Several chronic lymphocytic leukemia (CLL) studies have demonstrated promising efficacy with the combination of BCL2 and Bruton tyrosine kinase inhibitors; however, patients with CLL with del(17p) and/or TP53 mut...
Use of Low-Value Cancer Treatments in Medicare Advantage Versus Traditional Medicare [0.03%]
与传统医疗保险相比，Medicare优势计划中低值癌症治疗的使用情况
Jeah Jung,Caroline Carlin,Roger Feldman et al.
Jeah Jung et al.
Purpose: Medicare Advantage (MA) provides beneficiaries an option to receive Medicare benefits from private plans. Although MA covers over half of the Medicare population, limited information exists about how utilization ...
Phase II (Alliance A091802) Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma [0.03%]
阿维单抗联合西妥昔单抗与单纯阿维单抗治疗晚期皮肤鳞状细胞癌的II期（联盟A091802）随机试验
Dan P Zandberg,Jacob B Allred,Ari J Rosenberg et al.
Dan P Zandberg et al.
Purpose: Continued improvement in outcomes is needed for advanced cutaneous squamous cell carcinoma (cSCC). Methods: Alliance A091802 i...
Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study [0.03%]
用于局部晚期胰腺导管腺癌的新型联合治疗模式：随机、开放标签、关键性III期PANOVA-3研究（尼拉帕利+吉西他滨和白蛋白结合型紫杉醇）
Hani M Babiker,Vincent Picozzi,Sreenivasa R Chandana et al.
Hani M Babiker et al.
Purpose: Tumor treating fields (TTFields) use alternating electric fields to disrupt cancer cell proliferation. Feasibility of TTFields therapy with gemcitabine/nab-paclitaxel was previously demonstrated in patients with ...